Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CingulateCING +1.16%36 Cash-to-Debt is 4.52 as of Jun. 2026, which is 235% above its 10-year median of 1.35. GuruFocus rates CING with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 1,398 Biotechnology companies, Cingulate ranks worse than 55.22% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cingulate's cash to debt ratio for the quarter that ended in Jun. 2026 was 4.52.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cingulatecould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Cingulate's Cash-to-Debt or its related term are showing as below:
CING'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 1.35 Max: 42.91
Current: 4.52
During the past 7 years, Cingulate's highest Cash to Debt Ratio was 42.91. The lowest was 0.02. And the median was 1.35.
CING's Cash-to-Debt is ranked worse than 55.22% of 1398
companies
in the Biotechnology industry
Industry Median: 6.575
vs CING: 4.52
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cingulate Cash-to-Debt Related Terms
Cingulate Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cingulate's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Cingulate's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cingulate Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cingulate's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cingulate's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cingulate (CING) has a Cash-to-Debt of 4.52 as of Jun. 2026. This is 235% above median its historical median of 1.35. Over the past decade, Cingulate's Cash-to-Debt has ranged from 0.02 to 42.91. According to the industry distribution chart, Cingulate ranks #772 out of 1398 companies in the Biotechnology industry, placing it in the top 55.2%.
Is Cingulate's Cash-to-Debt too high?
Cingulate's current Cash-to-Debt of 4.52 is 235% above median its 10-year median of 1.35. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 42.91. The Biotechnology industry median Cash-to-Debt is 6.58. Cingulate's value of 4.52 is 31.3% below this industry median. Based on the distribution chart, Cingulate ranks #772 out of 1398 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cingulate has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's Cash-to-Debt compare to GANX and APLM?
According to the Biotechnology industry distribution chart, Cingulate ranks #772 out of 1398 companies for Cash-to-Debt. This places Cingulate in the lower half of its industry. The industry median Cash-to-Debt is 6.58. Cingulate's value of 4.52 is 31.3% below this benchmark. Historically, Cingulate's own Cash-to-Debt has ranged from 0.02 to 42.91 over the past decade. While the company's 10-year median is 1.35 vs. the industry median of 6.58, Cingulate has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.58, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cingulate's current Cash-to-Debt of 4.52 is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cingulate's current Cash-to-Debt is 4.52, which is 235% above median its own 10-year median of 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current Cash-to-Debt of 4.52. The current Cash-to-Debt is 4.52, which is 235% above median its 10-year median of 1.35 and 31.3% below the Biotechnology industry median of 6.58. Cingulate's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cingulate (CING), the current Cash-to-Debt is 4.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
36GF Score
Get the complete analysis for CING
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CING has been successfully added to your 
